Champions Oncology reports record annual revenue of $59.4M; FY2026 operating loss of $1.1M vs prior year income of $4.6M

CHAMPIONS ONCOLOGY, INC.

Record annual revenue $59.4M, up 4% YoY; Q4 revenue $13.8M, up 12% YoY.
FY2026 operating loss $1.1M (incl. $1.2M stock comp, $1.4M D&A) vs prior year operating income $4.6M.
Adjusted EBITDA $1.6M for FY2026, down from $7.1M prior year; Q4 adjusted EBITDA $158K positive.
Oncology services margin 48% for FY2026 vs 50% prior year; Q4 margin improved to 51% from 41%.
Cash $4.9M, no debt; continued investment in radiopharmaceuticals, data platform, commercial organization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.